RESUMO

This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to (177)Lu-DOTATATE and with lower abdominal uptake than (131)I-TATE. In addition, (131)I-DOTATATE showed significative tumour uptake, despite not so persistent after 24h. (131)I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy.

Assuntos

Radioisótopos do Iodo , Lutécio , Tumores Neuroendócrinos/diagnóstico por imagem , Radioisótopos , Somatostatina/análogos & derivados , Animais , Quelantes , Compostos Heterocíclicos com 1 Anel , Camundongos , Tumores Neuroendócrinos/radioterapia , Farmacocinética , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética , Somatostatina/farmacocinética , Distribuição Tecidual